MedTrace Logo

Comparison of Two Gait Re-training Modalities During a Cardiac Rehabilitation Stay: Benefit of Orienteering Walking

NCT06941597 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-12-24

No results posted yet for this study

Summary

Cardiovascular disease (CVD) is the leading cause of death in France for women and the second leading cause of death for men after cancer. They cause around 140,000 deaths every year, or almost 400 people every day throughout France. CVD also accounts for over a million hospital admissions a year, 160,000 of which are attributable to heart failure.

At present, cardiovascular rehabilitation centres mainly use exercise training methods based on sessions on cycloergometers and active walking (walking on a track and/or treadmill). Convinced of the added value of Orienteering, we have included it in our routine treatment as part of our Cardiac Rehabilitation programme, in addition to sessions on cycloergometers and active walking since 2021. As there is little literature on the subject in our population of interest, the aim of this study is to provide evidence of the relevance of orienteering in the cardiac rehabilitation programme.

We hypothesise that orienteering induces a similar cardiac response, amount of physical activity and perception of symptoms compared with an active walking session, while providing greater enjoyment of the activity.

Conditions

  • Cardiovascular Diseases (CVD)
  • Coronary Heart Disease (CHD)
  • Heart Failure
  • Congenital Heart Disease

Sponsors & Collaborators

  • Univ Brest, Laboratory ORPHY, F-29200 Brest, France

    collaborator UNKNOWN

  • Fondation Ildys

    lead OTHER

Principal Investigators

  • Klervie BAILLY · Fondation Ildys

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2025-10-05
Completion
2025-10-05

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06941597 on ClinicalTrials.gov